Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.
http://www.businesswire.com/news/topix/20130214005886/en
http://www.businesswire.com/news/topix/20130214005886/en
No comments:
Post a Comment